



## EGeen RNA Program Country Card – Ukraine



### Ukraine Overview



- Population: 44.43 million
- Five Largest Cities: Kiev, Kharkiv, Dnipropetrovsk, Odessa, Donetsk
- Language: Ukrainian (official); Russian
- EU Member: No
- Govt Type: Semi-Presidential Constitutional Republic
- Govt. Admin.: 24 Provinces + Kiev (capital), Crimea and Sebastopol
- Health System: Centralized, state-provisions and delivery; no insur:

### Clinical Trial Network / Comments



- HC Sites: ~ 2700 hospitals, declining; 90% inpatient; 18 university hospitals; 7.2 beds per 1000
- Highly centralized (ex-Soviet) HC delivery; 86% public, 27 admin sites; poor quality, short staffed
- Investigators: ICH GCP experienced, high quality, motivated, excellent data
- CRAs: Physicians, biologists, nurses; good relations with investigators
- Largest patient pool in CEE (exc. Russia); very high rates of cardiovascular disease, HIV
- High percentage of pediatric trials conducted; centralized pediatric healthcare for patient access


### EGeen Clinical Trial Support



- Full range of clinical trial services
- Patient recruitment, clinical monitoring, data management, biostatistics, regulatory
- Pharmacovigilance, project management, ethics review, quality assurance
- EU Qualified Person (QP) assistance to obtain EU GMP certificate for manufacturing reqs.
- Cost-effective EU / EE / non-EU importation partnerships and local IMP logistics
- Institutional relationships to proactively obtain contract approvals prior to regulatory filings as needed



### Ukraine – Clinical Trail Process Overview



### Ukraine Approval Process Highlights



- No Qualified Person (QP) required; Ukraine is not an EU member state
- RA approval in two stages; first as State Expert Center with MOH, then approval by MOH itself **NOTE**
- LEC review and approval only after MOH RA approvals
- All major submission documents need to be into local language
- CTA negotiations, signatures can run concurrent with RA approval process; no CEC approvals
- Importation licenses only after MOH approval **NOTE**
- Importation permit then required for each study drug shipment
- Summary: Time from QP ID to Importation of IMP estimated at **19 weeks**

Note: Summary time total is an estimated average of trial complexity